Use of the hyphenated LC-MS/MS technique and NMR/IR spectroscopy for the identification of exemestane stress degradation products during the drug development

Exemestane (6-Methyleneandrosta-1,4-diene-3,17-dione) active pharmaceutical ingredient (EE-3) was subjected to thermal, photolytic, oxidative, acidic and base stress conditions prescribed by the ICH (International Conference on Harmonization) guideline Q1A(R2). EE-3 was found to degrade in base, aci...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of pharmaceutical sciences 2017-11, Vol.109, p.389-401
Hauptverfasser: Stolarczyk, Elżbieta U., Rosa, Anna, Kubiszewski, Marek, Zagrodzka, Joanna, Cybulski, Marcin, Kaczmarek, Łukasz
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 401
container_issue
container_start_page 389
container_title European journal of pharmaceutical sciences
container_volume 109
creator Stolarczyk, Elżbieta U.
Rosa, Anna
Kubiszewski, Marek
Zagrodzka, Joanna
Cybulski, Marcin
Kaczmarek, Łukasz
description Exemestane (6-Methyleneandrosta-1,4-diene-3,17-dione) active pharmaceutical ingredient (EE-3) was subjected to thermal, photolytic, oxidative, acidic and base stress conditions prescribed by the ICH (International Conference on Harmonization) guideline Q1A(R2). EE-3 was found to degrade in base, acidic and oxidative conditions. Eleven new degradation products of EE-3 were characterized by the LC-MS/MS technique. One of these impurities was isolated and identified by the LC-MS/MS, NMR and IR techniques. The LC-MS/MS studies were carried out to establish fragmentation pathways of EE-3 and its new impurity. Based on the results obtained from different spectroscopic studies, this impurity was characterized as 3-hydroxy-1,6-dimethyl-oestratetraen-(1, 3, 5(10), 6)-17-one (EE-3Z). The degradation pathway of EE-3 leading to the generation of eleven products was proposed and this has not been reported so far. The separation of EE-3 from its impurities (process-related and degradants) was achieved using a Gemini C18 column (150mm×4.6mm×3μm) with gradient elution. The degradation products were well resolved from the main peak and its impurities, thus proving the method's stability and indicating power of the method. The method was validated according to the ICH guidelines for parameters such as specificity, limit of detection, limit of quantitation, precision, linearity, accuracy, robustness and system suitability. [Display omitted]
doi_str_mv 10.1016/j.ejps.2017.08.033
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1935385074</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0928098717304906</els_id><sourcerecordid>1935385074</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-6f4c99c1fa71898ac3fb862c4839eaef11cfdb285f4857e249b2e5e3229b9ef13</originalsourceid><addsrcrecordid>eNp9kU1vEzEQhi0EoqHwBzggH7nsxvZ-2RIXFFGolFCpH2fLa48TR9n1Ynsr8mP6X3GawpGTpfEzj2bmRegjJSUltF3uS9hPsWSEdiXhJamqV2hBeScK0jHyGi2IYLwggncX6F2Me0JIyzvyFl0wztum5e0CPT1EwN7itAO8O047GFUCg9erYnO33NzhBHo3ul8zYDUa_HNzu7y-xXECnYKP2k9HbH147nYGxuSs0yo5P56c8BsGiEmNgGMKECM2sA3KnIEpeDPrlItzcOP22WHCvM3QIxz8NGTde_TGqkOEDy_vJXq4-na_-lGsb75fr76uC101bSpaW2shNLWqo1xwpSvb85bpmlcCFFhKtTU9442tedMBq0XPoIGKMdGL_F1dos9nbx4q7xqTHFzUcDjk2f0cJRVVU_GGdHVG2RnV-QAxgJVTcIMKR0mJPMUi9_IUizzFIgmXOZbc9OnFP_cDmH8tf3PIwJczAHnLRwdBRu1g1GBcyLeWxrv_-f8AaX-h4Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1935385074</pqid></control><display><type>article</type><title>Use of the hyphenated LC-MS/MS technique and NMR/IR spectroscopy for the identification of exemestane stress degradation products during the drug development</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Stolarczyk, Elżbieta U. ; Rosa, Anna ; Kubiszewski, Marek ; Zagrodzka, Joanna ; Cybulski, Marcin ; Kaczmarek, Łukasz</creator><creatorcontrib>Stolarczyk, Elżbieta U. ; Rosa, Anna ; Kubiszewski, Marek ; Zagrodzka, Joanna ; Cybulski, Marcin ; Kaczmarek, Łukasz</creatorcontrib><description>Exemestane (6-Methyleneandrosta-1,4-diene-3,17-dione) active pharmaceutical ingredient (EE-3) was subjected to thermal, photolytic, oxidative, acidic and base stress conditions prescribed by the ICH (International Conference on Harmonization) guideline Q1A(R2). EE-3 was found to degrade in base, acidic and oxidative conditions. Eleven new degradation products of EE-3 were characterized by the LC-MS/MS technique. One of these impurities was isolated and identified by the LC-MS/MS, NMR and IR techniques. The LC-MS/MS studies were carried out to establish fragmentation pathways of EE-3 and its new impurity. Based on the results obtained from different spectroscopic studies, this impurity was characterized as 3-hydroxy-1,6-dimethyl-oestratetraen-(1, 3, 5(10), 6)-17-one (EE-3Z). The degradation pathway of EE-3 leading to the generation of eleven products was proposed and this has not been reported so far. The separation of EE-3 from its impurities (process-related and degradants) was achieved using a Gemini C18 column (150mm×4.6mm×3μm) with gradient elution. The degradation products were well resolved from the main peak and its impurities, thus proving the method's stability and indicating power of the method. The method was validated according to the ICH guidelines for parameters such as specificity, limit of detection, limit of quantitation, precision, linearity, accuracy, robustness and system suitability. [Display omitted]</description><identifier>ISSN: 0928-0987</identifier><identifier>EISSN: 1879-0720</identifier><identifier>DOI: 10.1016/j.ejps.2017.08.033</identifier><identifier>PMID: 28865686</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Androstadienes - chemistry ; Androstadienes - radiation effects ; Antineoplastic Agents - chemistry ; Antineoplastic Agents - radiation effects ; Aromatase Inhibitors - chemistry ; Aromatase Inhibitors - radiation effects ; Chromatography, Liquid ; Drug Contamination ; Drug Stability ; Exemestane ; Forced degradation ; Fragmentation pathway ; Hydrochloric Acid - chemistry ; Hydrogen Peroxide - chemistry ; Hydrogen-Ion Concentration ; Hydrolysis ; Impurity profile ; LC-MS/MS ; Magnetic Resonance Spectroscopy ; Oxidants - chemistry ; Oxidation-Reduction ; Photolysis ; Sodium Hydroxide - chemistry ; Spectrophotometry, Infrared ; Stability indicating method ; Tandem Mass Spectrometry ; Ultraviolet Rays</subject><ispartof>European journal of pharmaceutical sciences, 2017-11, Vol.109, p.389-401</ispartof><rights>2017 Elsevier B.V.</rights><rights>Copyright © 2017 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-6f4c99c1fa71898ac3fb862c4839eaef11cfdb285f4857e249b2e5e3229b9ef13</citedby><cites>FETCH-LOGICAL-c356t-6f4c99c1fa71898ac3fb862c4839eaef11cfdb285f4857e249b2e5e3229b9ef13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0928098717304906$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28865686$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stolarczyk, Elżbieta U.</creatorcontrib><creatorcontrib>Rosa, Anna</creatorcontrib><creatorcontrib>Kubiszewski, Marek</creatorcontrib><creatorcontrib>Zagrodzka, Joanna</creatorcontrib><creatorcontrib>Cybulski, Marcin</creatorcontrib><creatorcontrib>Kaczmarek, Łukasz</creatorcontrib><title>Use of the hyphenated LC-MS/MS technique and NMR/IR spectroscopy for the identification of exemestane stress degradation products during the drug development</title><title>European journal of pharmaceutical sciences</title><addtitle>Eur J Pharm Sci</addtitle><description>Exemestane (6-Methyleneandrosta-1,4-diene-3,17-dione) active pharmaceutical ingredient (EE-3) was subjected to thermal, photolytic, oxidative, acidic and base stress conditions prescribed by the ICH (International Conference on Harmonization) guideline Q1A(R2). EE-3 was found to degrade in base, acidic and oxidative conditions. Eleven new degradation products of EE-3 were characterized by the LC-MS/MS technique. One of these impurities was isolated and identified by the LC-MS/MS, NMR and IR techniques. The LC-MS/MS studies were carried out to establish fragmentation pathways of EE-3 and its new impurity. Based on the results obtained from different spectroscopic studies, this impurity was characterized as 3-hydroxy-1,6-dimethyl-oestratetraen-(1, 3, 5(10), 6)-17-one (EE-3Z). The degradation pathway of EE-3 leading to the generation of eleven products was proposed and this has not been reported so far. The separation of EE-3 from its impurities (process-related and degradants) was achieved using a Gemini C18 column (150mm×4.6mm×3μm) with gradient elution. The degradation products were well resolved from the main peak and its impurities, thus proving the method's stability and indicating power of the method. The method was validated according to the ICH guidelines for parameters such as specificity, limit of detection, limit of quantitation, precision, linearity, accuracy, robustness and system suitability. [Display omitted]</description><subject>Androstadienes - chemistry</subject><subject>Androstadienes - radiation effects</subject><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - radiation effects</subject><subject>Aromatase Inhibitors - chemistry</subject><subject>Aromatase Inhibitors - radiation effects</subject><subject>Chromatography, Liquid</subject><subject>Drug Contamination</subject><subject>Drug Stability</subject><subject>Exemestane</subject><subject>Forced degradation</subject><subject>Fragmentation pathway</subject><subject>Hydrochloric Acid - chemistry</subject><subject>Hydrogen Peroxide - chemistry</subject><subject>Hydrogen-Ion Concentration</subject><subject>Hydrolysis</subject><subject>Impurity profile</subject><subject>LC-MS/MS</subject><subject>Magnetic Resonance Spectroscopy</subject><subject>Oxidants - chemistry</subject><subject>Oxidation-Reduction</subject><subject>Photolysis</subject><subject>Sodium Hydroxide - chemistry</subject><subject>Spectrophotometry, Infrared</subject><subject>Stability indicating method</subject><subject>Tandem Mass Spectrometry</subject><subject>Ultraviolet Rays</subject><issn>0928-0987</issn><issn>1879-0720</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1vEzEQhi0EoqHwBzggH7nsxvZ-2RIXFFGolFCpH2fLa48TR9n1Ynsr8mP6X3GawpGTpfEzj2bmRegjJSUltF3uS9hPsWSEdiXhJamqV2hBeScK0jHyGi2IYLwggncX6F2Me0JIyzvyFl0wztum5e0CPT1EwN7itAO8O047GFUCg9erYnO33NzhBHo3ul8zYDUa_HNzu7y-xXECnYKP2k9HbH147nYGxuSs0yo5P56c8BsGiEmNgGMKECM2sA3KnIEpeDPrlItzcOP22WHCvM3QIxz8NGTde_TGqkOEDy_vJXq4-na_-lGsb75fr76uC101bSpaW2shNLWqo1xwpSvb85bpmlcCFFhKtTU9442tedMBq0XPoIGKMdGL_F1dos9nbx4q7xqTHFzUcDjk2f0cJRVVU_GGdHVG2RnV-QAxgJVTcIMKR0mJPMUi9_IUizzFIgmXOZbc9OnFP_cDmH8tf3PIwJczAHnLRwdBRu1g1GBcyLeWxrv_-f8AaX-h4Q</recordid><startdate>20171115</startdate><enddate>20171115</enddate><creator>Stolarczyk, Elżbieta U.</creator><creator>Rosa, Anna</creator><creator>Kubiszewski, Marek</creator><creator>Zagrodzka, Joanna</creator><creator>Cybulski, Marcin</creator><creator>Kaczmarek, Łukasz</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20171115</creationdate><title>Use of the hyphenated LC-MS/MS technique and NMR/IR spectroscopy for the identification of exemestane stress degradation products during the drug development</title><author>Stolarczyk, Elżbieta U. ; Rosa, Anna ; Kubiszewski, Marek ; Zagrodzka, Joanna ; Cybulski, Marcin ; Kaczmarek, Łukasz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-6f4c99c1fa71898ac3fb862c4839eaef11cfdb285f4857e249b2e5e3229b9ef13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Androstadienes - chemistry</topic><topic>Androstadienes - radiation effects</topic><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - radiation effects</topic><topic>Aromatase Inhibitors - chemistry</topic><topic>Aromatase Inhibitors - radiation effects</topic><topic>Chromatography, Liquid</topic><topic>Drug Contamination</topic><topic>Drug Stability</topic><topic>Exemestane</topic><topic>Forced degradation</topic><topic>Fragmentation pathway</topic><topic>Hydrochloric Acid - chemistry</topic><topic>Hydrogen Peroxide - chemistry</topic><topic>Hydrogen-Ion Concentration</topic><topic>Hydrolysis</topic><topic>Impurity profile</topic><topic>LC-MS/MS</topic><topic>Magnetic Resonance Spectroscopy</topic><topic>Oxidants - chemistry</topic><topic>Oxidation-Reduction</topic><topic>Photolysis</topic><topic>Sodium Hydroxide - chemistry</topic><topic>Spectrophotometry, Infrared</topic><topic>Stability indicating method</topic><topic>Tandem Mass Spectrometry</topic><topic>Ultraviolet Rays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stolarczyk, Elżbieta U.</creatorcontrib><creatorcontrib>Rosa, Anna</creatorcontrib><creatorcontrib>Kubiszewski, Marek</creatorcontrib><creatorcontrib>Zagrodzka, Joanna</creatorcontrib><creatorcontrib>Cybulski, Marcin</creatorcontrib><creatorcontrib>Kaczmarek, Łukasz</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stolarczyk, Elżbieta U.</au><au>Rosa, Anna</au><au>Kubiszewski, Marek</au><au>Zagrodzka, Joanna</au><au>Cybulski, Marcin</au><au>Kaczmarek, Łukasz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of the hyphenated LC-MS/MS technique and NMR/IR spectroscopy for the identification of exemestane stress degradation products during the drug development</atitle><jtitle>European journal of pharmaceutical sciences</jtitle><addtitle>Eur J Pharm Sci</addtitle><date>2017-11-15</date><risdate>2017</risdate><volume>109</volume><spage>389</spage><epage>401</epage><pages>389-401</pages><issn>0928-0987</issn><eissn>1879-0720</eissn><abstract>Exemestane (6-Methyleneandrosta-1,4-diene-3,17-dione) active pharmaceutical ingredient (EE-3) was subjected to thermal, photolytic, oxidative, acidic and base stress conditions prescribed by the ICH (International Conference on Harmonization) guideline Q1A(R2). EE-3 was found to degrade in base, acidic and oxidative conditions. Eleven new degradation products of EE-3 were characterized by the LC-MS/MS technique. One of these impurities was isolated and identified by the LC-MS/MS, NMR and IR techniques. The LC-MS/MS studies were carried out to establish fragmentation pathways of EE-3 and its new impurity. Based on the results obtained from different spectroscopic studies, this impurity was characterized as 3-hydroxy-1,6-dimethyl-oestratetraen-(1, 3, 5(10), 6)-17-one (EE-3Z). The degradation pathway of EE-3 leading to the generation of eleven products was proposed and this has not been reported so far. The separation of EE-3 from its impurities (process-related and degradants) was achieved using a Gemini C18 column (150mm×4.6mm×3μm) with gradient elution. The degradation products were well resolved from the main peak and its impurities, thus proving the method's stability and indicating power of the method. The method was validated according to the ICH guidelines for parameters such as specificity, limit of detection, limit of quantitation, precision, linearity, accuracy, robustness and system suitability. [Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>28865686</pmid><doi>10.1016/j.ejps.2017.08.033</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0928-0987
ispartof European journal of pharmaceutical sciences, 2017-11, Vol.109, p.389-401
issn 0928-0987
1879-0720
language eng
recordid cdi_proquest_miscellaneous_1935385074
source MEDLINE; Elsevier ScienceDirect Journals
subjects Androstadienes - chemistry
Androstadienes - radiation effects
Antineoplastic Agents - chemistry
Antineoplastic Agents - radiation effects
Aromatase Inhibitors - chemistry
Aromatase Inhibitors - radiation effects
Chromatography, Liquid
Drug Contamination
Drug Stability
Exemestane
Forced degradation
Fragmentation pathway
Hydrochloric Acid - chemistry
Hydrogen Peroxide - chemistry
Hydrogen-Ion Concentration
Hydrolysis
Impurity profile
LC-MS/MS
Magnetic Resonance Spectroscopy
Oxidants - chemistry
Oxidation-Reduction
Photolysis
Sodium Hydroxide - chemistry
Spectrophotometry, Infrared
Stability indicating method
Tandem Mass Spectrometry
Ultraviolet Rays
title Use of the hyphenated LC-MS/MS technique and NMR/IR spectroscopy for the identification of exemestane stress degradation products during the drug development
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T02%3A52%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20the%20hyphenated%20LC-MS/MS%20technique%20and%20NMR/IR%20spectroscopy%20for%20the%20identification%20of%20exemestane%20stress%20degradation%20products%20during%20the%20drug%20development&rft.jtitle=European%20journal%20of%20pharmaceutical%20sciences&rft.au=Stolarczyk,%20El%C5%BCbieta%20U.&rft.date=2017-11-15&rft.volume=109&rft.spage=389&rft.epage=401&rft.pages=389-401&rft.issn=0928-0987&rft.eissn=1879-0720&rft_id=info:doi/10.1016/j.ejps.2017.08.033&rft_dat=%3Cproquest_cross%3E1935385074%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1935385074&rft_id=info:pmid/28865686&rft_els_id=S0928098717304906&rfr_iscdi=true